Core Viewpoint - Fuhong Hanlin (02696) shares have increased by over 5%, currently up 6.02% at HKD 68.7, with a trading volume of HKD 34.25 million [1] Group 1: Company Developments - On November 12, the CDE announced that Fuhong Hanlin's PD-1 antibody drug, Surulitinib injection (H drug), is proposed to be included as a breakthrough therapy for use in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer, marking its first recognition for this status [1] - The H drug is noted as the first PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer globally [1] Group 2: Investment Activity - On November 6 and November 10, Boyu Capital purchased 262,500 shares and 80,000 shares of Fuhong Hanlin's H shares, increasing their holdings from 5.84% to 7% [1] - Earlier, on June 18, Boyu Capital had invested HKD 21.27 million to increase their stake from 4.89% to 5.15%, surpassing the 5% threshold for mandatory disclosure [1]
港股异动 | 复宏汉霖(02696)再涨超5% H药拟首次纳入突破性疗法 博裕资本继续增持公司股份